Professor Farid Saad

Professor Farid Saad

Bayer AG, Berlin (Germany)

Farid Saad worked for various pharmaceutical companies as specialist for reproductive endocrinology, pediatric endocrinology, andrology, endocrinology of male aging, and hormonal male contraception in clinical development, scientific and global medical affairs. He retired in 2019 and keeps working as a consultant for Bayer AG in Germany. Farid Saad has authored and co-authored more than 150 peer-reviewed papers and more than 700 scientific abstracts. He received honorary professorships in clinical research and endocrinology at Gulf Medical University, Ajman, U.A.E., and at Men’s Health Reproduction Study Center, Hang Tuah University, Surabaya, Indonesia, and serves as a lecturer at Dresden International University, Dresden, Germany.

Presentations

Improvements of blood pressure, heart rate, and pulse pressure in men with hypogonadism and type 2 diabetes, with and without long-term testosterone therapy

Event: ESC Congress 2021 - The Digital Experience

Topic: Clinical

Session: Hypertension e-posters

Access

Improved glycaemic control and reduced incidence of myocardial infarctions, strokes, and mortality in men with hypogonadism and type 2 diabetes, with and without long-term testosterone therapy

Event: ESC Congress 2021 - The Digital Experience

Topic: Cardiovascular Disease in the Elderly

Session: Cardiovascular Disease in Special Populations ePosters

Access

Effect of testosterone therapy on cardiovascular risk factors, major adverse cardiovascular events and mortality in men with functional hypogonadism and cardiovascular disease in a real-world registry

Event: ESC Congress 2020

Topic: Cardiovascular Disease in the Elderly

Session: Cardiovascular Disease in the Elderly

Access

Significant reduction of Framingham risk score in hypogonadal men receiving long-term testosterone therapy: real-life evidence from a 10-year registry

Event: ESC Congress 2018

Topic: Scores

Session: Controversies in cardiovascular risk assessment and prevention

Access

Major adverse cardiovascular events (MACE) are reduced in testosterone-treated vs. untreated hypogonadal men: real-life evidence from a controlled registry study

Event: ESC Congress 2017

Topic: Primary cardiovascular prevention: interventions and outcomes

Session: Prevention general

Access

Long-term testosterone treatment in hypogonadal men may be effective in secondary prevention of major adverse cardiovascular events (MACE) with a history of cardiovascular disease (CVD)

Event: ESC Congress 2016

Topic: Primary cardiovascular prevention: interventions and outcomes

Session: Predicting outcomes in cardiac vascular disease

Access

ESC 365 is supported by

Explore sponsored resources

Professor Farid Saad

Biography

Contributor content

Improvements of blood pressure, heart rate, and pulse pressure in men with hypogonadism and type 2 diabetes, with and without long-term testosterone therapy

Improved glycaemic control and reduced incidence of myocardial infarctions, strokes, and mortality in men with hypogonadism and type 2 diabetes, with and without long-term testosterone therapy

Effect of testosterone therapy on cardiovascular risk factors, major adverse cardiovascular events and mortality in men with functional hypogonadism and cardiovascular disease in a real-world registry

Significant reduction of Framingham risk score in hypogonadal men receiving long-term testosterone therapy: real-life evidence from a 10-year registry

Major adverse cardiovascular events (MACE) are reduced in testosterone-treated vs. untreated hypogonadal men: real-life evidence from a controlled registry study

Long-term testosterone treatment in hypogonadal men may be effective in secondary prevention of major adverse cardiovascular events (MACE) with a history of cardiovascular disease (CVD)

ESC 365 is supported by

Professor Farid Saad Follow

Biography

Contributor content

Improvements of blood pressure, heart rate, and pulse pressure in men with hypogonadism and type 2 diabetes, with and without long-term testosterone therapy

Improved glycaemic control and reduced incidence of myocardial infarctions, strokes, and mortality in men with hypogonadism and type 2 diabetes, with and without long-term testosterone therapy

Effect of testosterone therapy on cardiovascular risk factors, major adverse cardiovascular events and mortality in men with functional hypogonadism and cardiovascular disease in a real-world registry

Significant reduction of Framingham risk score in hypogonadal men receiving long-term testosterone therapy: real-life evidence from a 10-year registry

Major adverse cardiovascular events (MACE) are reduced in testosterone-treated vs. untreated hypogonadal men: real-life evidence from a controlled registry study

Long-term testosterone treatment in hypogonadal men may be effective in secondary prevention of major adverse cardiovascular events (MACE) with a history of cardiovascular disease (CVD)

ESC 365 is supported by

Professor Farid Saad